Physician profile
Kyle D Lemond
NPI 1609303015
$6,168.83
in general payments reported to CMS, 2019-2025
38 companies · $1,723 in 2025
The $1,723 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $176 · 2021: $757 · 2022: $395 · 2023: $1,408 · 2024: $1,710 · 2025: $1,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,840.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,473.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $549.67 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $512.44 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $490.06 | 2021-2025 | |
| Novo Nordisk INC | $457.34 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $357.42 | 2020-2025 | |
| Amgen INC. | $353.73 | 2020-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $325.99 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $246.72 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Axsome Therapeutics, INC. | $211.02 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.40 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $160.58 | 2020-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Janssen Pharmaceuticals, INC | $92.77 | 2021-2022 | |
| Corium, LLC | $72.57 | 2023-2025 | Azstarys |
| Inari Medical, INC. | $61.09 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Lemond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.